ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

elegrobart

Also written as “VRDN-003” and “ZL-1109 (VRDN-003)”.

Its studies are mostly in Graves Ophthalmopathy, led by 2 companies.

Drug pageElegrobart: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 1, 20245 company-led studies, 4 open or runningNext primary completion: Mar 14, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viridian Therapeuticsits history only43 open or runningphase 3since Oct 1, 2024Oct 1, 2024none ahead
Zai Lab11 open or runningphase 3since Oct 1, 2025Oct 1, 2025Mar 14, 2027phase 3 · NCT07211776

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Zai Lab only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2025Named elegrobartINNProposed as its International Nonproprietary Name in WHO's List 132 · before, VRDN-003
  2. Oct 1, 2025First study: phase 3 study in Graves OphthalmopathyFirst studyNCT07211776 · 108 enrolled · China

Ahead

  1. Mar 14, 2027Primary completion: phase 3 study in Graves OphthalmopathyNCT07211776

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Zai Lab leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07211776Graves Ophthalmopathy · China3Active, not recruitingMar 14, 2027108

How it is read

Names in the registry

  • “VRDN-003”, 4 entries
  • “ZL-1109 (VRDN-003)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.